Top startup acquisitions · Healthtech & bio

Top Healthtech & bio startup acquisitions in May 2026

We tracked 9 startup exits in May 2026. 5 disclosed a price, worth $7.85bn in total. The biggest was Bayer buying Perfuse Therapeutics for $2.45bn, ahead of UCB and Candid Therapeutics at $2.2bn.

All Healthtech & bio startup acquisitions →

#DateAcquirer → StartupSectorLocationPriceSize
16 MayBayer → Perfuse TherapeuticsBayer agrees to acquire eye-drug developer Perfuse Therapeutics for up to $2.45 billionHealthtech & bioSouth San Francisco, United States$2.45bn$1bn+
24 MayUCB → Candid TherapeuticsUCB agrees to buy Candid Therapeutics for $2 billion upfront in deal worth up to $2.2 billionHealthtech & bioSan Diego, United States$2.2bn$1bn+
326 MayEli Lilly → CurevoEli Lilly agrees to buy shingles vaccine developer Curevo for up to $1.5 billionHealthtech & bioBothell, United States$1.5bn$1bn+
47 MayRoche → PathAIRoche agrees to buy digital pathology company PathAI for up to $1.05 billionHealthtech & bioBoston, United States$1.05bn$1bn+
520 MayMedtronic → SPR TherapeuticsMedtronic agrees to buy SPR Therapeutics for $650 million in cashHealthtech & bioCleveland, United States$650m$250m–1bn
626 MaySwoop → NimbleSwoop acquires Nimble, a prescription platform for independent pharmacies, to reach patientsHealthtech & bioUnited StatesUndisclosedUndisclosed
720 MayIntegrated Home Care Services → DinaIntegrated Home Care Services acquires Dina, an AI care coordination platform for in-home careHealthtech & bioChicago, United StatesUndisclosedUndisclosed
812 MayFunction Health → SuppCoFunction Health acquires supplement-rating app SuppCo from GroupMe founder Steve MartocciHealthtech & bioNew York, United StatesUndisclosedUndisclosed
96 MayDoctolib → MedicusDoctolib acquires London GP software maker Medicus to enter the UKHealthtech & bioLondon, United KingdomUndisclosedUndisclosed